You are here
Gossypol overcomes stroma-mediated resistance to the BCL2 inhibitor ABT-737 in chronic lymphocytic leukemia cells ex vivo
Soderquist R, Bates DJ, Danilov AV, Eastman A.
Leukemia. May 2013 [Epub ahead of print]
Chronic lymphocytic leukemia (CLL) is characterized by the deregulated accumulation and persistence of B lymphocytes in the blood. Although the exact causes of CLL are unknown, the evasion of apoptosis through the aberrant expression of B-cell lymphoma 2 (BCL2)-family proteins is a common feature. A class of compounds, termed Bcl-2 homology domain 3 (BH3) mimetics, has been developed to directly inhibit BCL2 proteins and selectively kill tumor cells.